BR112021020295A2 - Agentes antiproliferativos para o tratamento de pah - Google Patents
Agentes antiproliferativos para o tratamento de pahInfo
- Publication number
- BR112021020295A2 BR112021020295A2 BR112021020295A BR112021020295A BR112021020295A2 BR 112021020295 A2 BR112021020295 A2 BR 112021020295A2 BR 112021020295 A BR112021020295 A BR 112021020295A BR 112021020295 A BR112021020295 A BR 112021020295A BR 112021020295 A2 BR112021020295 A2 BR 112021020295A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- salts
- treatment
- compositions
- pah
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção refere-se aos compostos de fórmula geral i em que a, r1, r2, r3 e r4 são como aqui definidos, e os sais farmaceuticamente aceitáveis dos mesmos; às composições farmacêuticas compreendendo tais compostos e sais; aos métodos de uso de tais compostos, sais e composições para o tratamento de hipertensão pulmonar e doenças relacionadas, como hipertensão arterial pulmonar; aos métodos de uso de tais compostos, sais e composições para o tratamento de crescimento anormal de células, tal como câncer; e aos processos para preparar tais compostos, sais e composições.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962836340P | 2019-04-19 | 2019-04-19 | |
| US202062981620P | 2020-02-26 | 2020-02-26 | |
| PCT/IB2020/053550 WO2020212865A1 (en) | 2019-04-19 | 2020-04-15 | Anti-proliferative agents for treating pah |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021020295A2 true BR112021020295A2 (pt) | 2021-12-14 |
Family
ID=70465141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021020295A BR112021020295A2 (pt) | 2019-04-19 | 2020-04-15 | Agentes antiproliferativos para o tratamento de pah |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11203594B2 (pt) |
| EP (1) | EP3956031A1 (pt) |
| JP (1) | JP2022529930A (pt) |
| KR (1) | KR20220003565A (pt) |
| CN (1) | CN114007697A (pt) |
| AU (1) | AU2020260018A1 (pt) |
| BR (1) | BR112021020295A2 (pt) |
| CA (1) | CA3136880C (pt) |
| IL (1) | IL287374A (pt) |
| MX (1) | MX2021012491A (pt) |
| SG (1) | SG11202111533XA (pt) |
| TW (1) | TWI744866B (pt) |
| UY (1) | UY38665A (pt) |
| WO (1) | WO2020212865A1 (pt) |
| ZA (1) | ZA202107695B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115551856A (zh) * | 2020-02-28 | 2022-12-30 | 重庆复尚源创医药技术有限公司 | 作为cdk2/4/6抑制剂的化合物 |
| CN113125602A (zh) * | 2021-04-16 | 2021-07-16 | 山东铂源药业有限公司 | 一种哌柏西利中残留溶剂的检测方法 |
| CN114773391A (zh) * | 2022-03-24 | 2022-07-22 | 联碳新材料技术(杭州)有限公司 | 一种含氟过渡金属配合物、其制备方法和应用 |
| CN114751884A (zh) * | 2022-05-06 | 2022-07-15 | 河南应用技术职业学院 | 一种（3s,4r）-4-氨基氧杂环己-3-醇的合成方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| DK0580860T4 (da) | 1991-04-16 | 2005-03-21 | Nippon Shinyaku Co Ltd | Fremgangsmåde til fremstilling af en fast dispersion |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| CA2575804A1 (en) * | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinones used as plk (polo like kinase) inhibitors |
| EP3102577B1 (en) * | 2014-02-07 | 2018-07-18 | Principia Biopharma Inc. | Quinolone derivatives as fibroblast growth factor receptor inhibitors |
| SI3497103T1 (sl) * | 2016-08-15 | 2021-07-30 | Pfizer Inc. | Zaviralci piridopirimdiona CDK2/4/6 |
| CA3040815C (en) | 2016-10-20 | 2021-07-20 | Steven Martin Evans | Anti-proliferative agents for treating pah |
-
2020
- 2020-04-15 MX MX2021012491A patent/MX2021012491A/es unknown
- 2020-04-15 SG SG11202111533XA patent/SG11202111533XA/en unknown
- 2020-04-15 CA CA3136880A patent/CA3136880C/en active Active
- 2020-04-15 BR BR112021020295A patent/BR112021020295A2/pt unknown
- 2020-04-15 KR KR1020217037811A patent/KR20220003565A/ko unknown
- 2020-04-15 WO PCT/IB2020/053550 patent/WO2020212865A1/en active Application Filing
- 2020-04-15 CN CN202080044516.XA patent/CN114007697A/zh active Pending
- 2020-04-15 EP EP20721747.2A patent/EP3956031A1/en active Pending
- 2020-04-15 JP JP2021561600A patent/JP2022529930A/ja not_active Withdrawn
- 2020-04-15 AU AU2020260018A patent/AU2020260018A1/en not_active Abandoned
- 2020-04-15 US US16/849,329 patent/US11203594B2/en active Active
- 2020-04-16 UY UY0001038665A patent/UY38665A/es unknown
- 2020-04-17 TW TW109112960A patent/TWI744866B/zh active
-
2021
- 2021-10-12 ZA ZA2021/07695A patent/ZA202107695B/en unknown
- 2021-10-18 IL IL287374A patent/IL287374A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11203594B2 (en) | 2021-12-21 |
| US20200331909A1 (en) | 2020-10-22 |
| EP3956031A1 (en) | 2022-02-23 |
| WO2020212865A1 (en) | 2020-10-22 |
| CN114007697A (zh) | 2022-02-01 |
| UY38665A (es) | 2020-11-30 |
| CA3136880A1 (en) | 2020-10-22 |
| CA3136880C (en) | 2023-09-19 |
| TWI744866B (zh) | 2021-11-01 |
| ZA202107695B (en) | 2023-04-26 |
| SG11202111533XA (en) | 2021-11-29 |
| MX2021012491A (es) | 2022-01-24 |
| IL287374A (en) | 2021-12-01 |
| KR20220003565A (ko) | 2022-01-10 |
| TW202104224A (zh) | 2021-02-01 |
| AU2020260018A1 (en) | 2021-11-04 |
| JP2022529930A (ja) | 2022-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021020295A2 (pt) | Agentes antiproliferativos para o tratamento de pah | |
| BR112021012635A2 (pt) | Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2 | |
| BR112019002610A2 (pt) | piridopirimidinonas inibidoras de cdk2/4/6 | |
| BR112021023750A2 (pt) | Compostos para tratamento de doenças pd-l1 | |
| BR112021025528A2 (pt) | Derivados de sulfonamida de benzisoxazol | |
| BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
| BR112021022659A2 (pt) | Compostos triarílicos para o tratamento de doenças pd-l1 | |
| BR112017024331A2 (pt) | composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto | |
| BR112012027062B8 (pt) | composto, processo para a preparação de um composto e usos do mesmo | |
| BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
| UY37900A (es) | Nuevos derivados de rapamicina | |
| BR112016029612A2 (pt) | compostos de di-hidroisoquinolinona substituídos | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| BR112019003519A2 (pt) | compostos de sulfonimidoilpurinona 7-substituídos para o tratamento e profilaxia de infecção por vírus | |
| DOP2013000238A (es) | Derivados de nucleosidos 2'-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| BR112014013974A8 (pt) | derivados de sulfonamida benzílicos como moduladores de rorc | |
| BR112022006279A2 (pt) | Heteroaril-bifenil aminas para o tratamento de doenças pd-l1 | |
| BR112012022125A2 (pt) | composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente | |
| BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
| BR112021022536A2 (pt) | Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo | |
| BR112022006018A2 (pt) | Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1 | |
| CO2021005532A2 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| BR112013017362A2 (pt) | composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores | |
| BR112017023959A2 (pt) | novos compostos de sulfonimidoilpurinona e derivados para o tratamento e profilaxia de infecção por vírus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: PFIZER INC. (US) |